The ICICI Group, or the Industrial Credit and Investment Corporation of India, is one of India’s largest and most diversified financial services conglomerates. Established in 1955, the group has played a significant role in the country’s economic development by providing a broad range of banking and financial services.
ICICI Group publicly holds 259 stocks with a net worth of more than Rs. 4.96 lakh crores, according to the sources.
Following are a few pharma stocks in which ICICI Group bought fresh stake in the September 2024 quarter:
Amrutanjan Health Care Limited
With a market capitalisation of Rs. 2,049 crores, the stock moved up by around 3 percent on BSE to Rs. 706 on Thursday.
According to the September 2024 shareholding data available with the BSE, ICICI Group via ICICI Prudential FMCG Fund bought around 7.06 lakh equity shares or a 2.44 percent stake in Amrutanjan Health Care.
In Q2 FY25, the company witnessed a significant growth in its revenue from operations, reaching Rs. 110 crores, a rise of around 11.2 percent YoY, accompanied by net profit growth of nearly 71.4 percent YoY to Rs. 12 crores.
Over the last one year, the stock has delivered positive returns of about 18.3 percent, and has gained nearly 13.6 percent year-to-date.
Incorporated in 1936, Amrutanjan Health Care Limited is engaged in the business of manufacture, supply, and sale of products in pain management, congestion management, beverages and hygiene and services in pain management.
MedPlus Health Services Limited
With a market capitalisation of Rs. 8,418.5 crores, the stock moved up by around 4.5 percent on BSE to Rs. 714.9 on Thursday.
According to the September 2024 shareholding data available with the BSE, ICICI Group via ICICI Prudential Pharma Healthcare and Diaganostic bought around 56.8 lakh equity shares or a 4.75 percent stake in MedPlus Health Services.
In Q2 FY25, the company witnessed a significant growth in its revenue from operations, reaching Rs. 1,576 crores, a rise of around 12 percent YoY, accompanied by net profit growth of nearly 160 percent YoY to Rs. 39 crores.
Over the last one year, the stock has delivered negative returns of about 13.6 percent, as well as nearly 5 percent returns year-to-date.
MedPlus Health Services Limited is primarily engaged in the business of provision of diagnostic services, pathological services and laboratory testing services, along with the manufacturing, purchase and sale of pharmaceuticals and other general items.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
